LIXTE director swaps 25K options for RSUs
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes entered into a Stock Option Cancellation Agreement on April 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes entered into a Stock Option Cancellation Agreement on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price that had been granted on December 24, 2025 and, in exchange, granted 25,000 restricted share units (RSUs).
Each RSU represents a right to receive one share of common stock upon vesting, and all 25,000 RSUs vested immediately on the grant date. Following these compensation-related transactions, Lourdes directly holds 25,000 shares of common stock, with no remaining options from the canceled grant.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Felix Lourdes
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 25,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 25,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 25,000 shares (Direct)
Footnotes (2)
- F1. On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.
- F2. The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.
Key Figures
Options canceled: 25,000 options
Option exercise price: $4.05 per share
RSUs granted: 25,000 RSUs
+2 more
5 metrics
Options canceled
25,000 options
Canceled on April 15, 2026 under Stock Option Cancellation Agreement
Option exercise price
$4.05 per share
Exercise price of 25,000 canceled options granted December 24, 2025
RSUs granted
25,000 RSUs
Granted April 15, 2026 in exchange for canceled options
RSU vesting
25,000 RSUs vest immediately
Each RSU converts into one share of common stock upon vesting
Shares held after
25,000 shares
Common stock directly owned by Felix Lourdes following transactions
Key Terms
Stock Option Cancellation Agreement, restricted share units, 2020 Stock Incentive Plan, vest, +1 more
5 terms
Stock Option Cancellation Agreement financial
"the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026"
2020 Stock Incentive Plan financial
"The RSUs were granted pursuant to the applicable award agreement ... and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."
vest financial
"The 25,000 RSUs vest immediately upon grant."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
vesting financial
"The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did LIXT director Felix Lourdes report on this Form 4?
Felix Lourdes reported canceling 25,000 stock options and receiving 25,000 restricted share units in exchange. The RSUs vest immediately and convert into common stock, reflecting a restructuring of his equity compensation rather than any open-market buying or selling activity.
How many LIXT options were canceled and at what exercise price?
The filing shows 25,000 stock options were canceled, each with a $4.05 exercise price. These options had a vesting schedule with 50% on the grant date and 12.5% vesting on specified quarter-end dates until fully vested, before being replaced by RSUs.
What did Felix Lourdes receive in exchange for the canceled LIXT options?
In exchange for canceling 25,000 options, Felix Lourdes received 25,000 restricted share units. Each RSU represents a contingent right to one share of LIXTE common stock and all 25,000 RSUs vested immediately upon grant under the company’s 2020 Stock Incentive Plan.
Did the LIXT Form 4 show any open-market buys or sells by Felix Lourdes?
The Form 4 does not show any open-market purchases or sales. Instead, it records a disposition of options back to the issuer and a compensatory grant of RSUs that vested immediately, making this a non-market, compensation-related adjustment to his equity holdings.
Under which plan were the new LIXT RSUs granted to Felix Lourdes?
The 25,000 RSUs granted to Felix Lourdes were issued under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. They are documented in an award agreement dated April 15, 2026 and represent equity-based compensation tied to his continued service as a director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
